Heart Transplant Market Related Reports and Intelligence in Organ Transplantation

Revenue, 2025

USD 13.62 Billion

Forecast, 2035

USD 35.79 Billion

CAGR, 2026-2035

10.14%

Report Coverage

Global

Heart Transplant Market Trends for 2026

The global heart transplant market size was estimated at USD 13.62 billion in 2025 and is predicted to increase from USD 15.01 billion in 2026 to approximately USD 35.79 billion by 2035, expanding at a CAGR of 10.14% from 2026 to 2035.

The heart transplant market is growing, as major heart transplant patients live longer, enjoy an advanced quality of life, have increased energy levels, and enhanced general well-being.

Key Takeaways

• The heart transplant market will likely exceed USD 15.01 billion by 2026.
• Valuation is projected to hit USD 35.79 billion by 2035.
• Estimated to grow at a CAGR of 10.14% starting from 2026 to 2035.
• North America dominated the heart transplant market in 2025.
• Asia Pacific is expected to grow at the fastest CAGR in the market during the forecast period.
• By type of donor, the deceased donor segment dominated the market in 2025.
• By type of donor, the living donor segment is expected to fastest growing in the market during the forecast period.
• By age group, the adult segment dominated in 2025.
• By age group, the pediatric segment is expected to fastest growing in the market during the forecast period.
• By surgical technique, the orthotopic transplantation segment dominated the market in 2025.
• By surgical technique, the minimally invasive surgery segment is expected fastest growing in the market during the forecast period.
• By post-transplant care, the immunosuppressive therapy segment dominated the market in 2025.
• By post-transplant care, the cardiac rehabilitation segment is expected to fastest growing in the market during the forecast period.

What Factors are Supporting the Growth of the Heart Transplant Market?

The heart transplant market is growing because of rising cardiovascular diseases, especially in the elderly population. An orthotopic heart transplant is the most commonly utilized technique, whereas a heterotopic transplant has described and performed. Patients with progressive heart failure need mechanical circulatory support, and those with inotropic support have a poor prognosis. A heart transplant is a challenging surgical process in which a failing or diseased heart is replaced with a healthy donor heart from someone who has passed away. It’s generally done for patients with end-stage heart failure or complex heart failure. Heart transplantation is a well-established and life-saving treatment for qualified patients.

Increasing Cardiac Diseases-Related Emergency

How is AI Governing the Heart Transplant Market?

Integration of AI-driven technology in heart transplant drives market growth, as applications for AI-based technology include identifying heart disease, managing strokes rapidly, and improving diagnostic radiology abilities. These AI-based tools and processes also play a significant role in healthcare education. AI is applied to optimize the matching technology among donors and recipients, an important step in ensuring that the transplanted heart is compatible with the recipient’s body. AI-driven technology rapidly analyzes a patient’s health history, type of blood, and genetic markers, along with other factors, to forecast the likelihood of organ refusal or other challenges. This allows physicians to make more up-to-date decisions related to which donor heart to use and which recipient is the ideal match. AI-driven technology supports monitoring patients after the transplant, tracing significant signs and identifying early signs of organ rejection, which significantly enhances long-term results.

Trends & Future Outlook in the Heart Transplant Market

• Donation after Circulatory Death (DCD): DCD is practiced widely; organ donation is often considered a routine part of end-of-life care. DCD is growing in response to a lack of organs available for transplant. It enhances the quality of life and increases the life expectancy of patients with end-stage organ failure.
• Ex Vivo Organ Perfusion: Ex vivo organ perfusion (EVOP) is applied for whole organ preservation, and the significant focus is to enhance the results of donor organs for transplantation. It supports increasing the quality of the organ, enabling better results for transplant patients.
• HCV-Positive Donors: Using organs from donors who have HCV and are Ab+/RNA + surge access to transplantation, also significantly lowers the time on the waiting list, with excellent outcomes in graft function, converting this therapy into an affordable approach in the medium and long terms.

Executive Summary Table

Segmentation Analysis

By Type of Donor Insights

Which Type of Donor Led the Heart Transplant Market in 2025?

In 2025, the deceased donor segment held the dominant market in 2025, due to from this type of donor organs are available more readily than living donors, as they come from deceased patients who have consented to organ donation. Organs from a deceased donor support one or more patients by donating various organs that the patients require. A deceased donor transplant eliminates organs from a dead person who has been accepted to donate their heart.

Living Donor

Whereas the living donor segment is the fastest-growing in the market, a living donor transplant includes a living patient who donates an organ for transplantation, like a kidney or heart, to a patient in need. Living donor transplants are more significant and reliable, as the screening is done before the transplant to ensure compatibility with the recipient before the transplant. The quality of the organ is higher as it comes from a well-living donor.

By Age Group Insights

Why did the Adult Segment Dominate the Market in 2025?

The adult segment is dominant in the heart transplant market in 2025, as heart transplants in adult is performed in patients with refractory acute and chronic heart failure. Patients with serious, chronic symptoms such as fatigue and shortness of breath that persist despite optimum and maximum medical therapy (GDMT). Adults born with heart defects who have developed severe and irreversible failure.

Pediatric

Whereas the pediatric segment is the fastest-growing in the market, as pediatric heart transplantation (pHTx) shows a small (14%) but very significant and specific part in the field of cardiac transplantation. It presents hopeful uses in continuity of follow-up, medication titration, and patient counseling. Pediatric cardiac transplantation is performed as treatment for palliated congenital heart disease (CHD) and Cardiomyopathy refractory to operating and medical services.

By Surgical Technique: Insights

Why did the Orthotopic Transplantation Segment Dominate the Market in 2025?

The orthotopic transplantation segment is dominant in the heart transplant market in 2025, as it is a well-established and commonly utilized technology for end-stage heart failure patients.  With these processes, there is less tricuspid spewing, less sinus node dysfunction, less atrial dilatation, and a decreasing requirement for pacemaker implantation. The process replaces the deteriorating organ with a healthy donor heart, with the goal of restoring normal heart function and improving overall well-being.

Minimally Invasive Surgery

Whereas the minimally invasive surgery segment is the fastest-growing in the market, as providing smaller incisions, shorter recovery periods, lower pain and complications, and better cosmetic outcomes, MICS has become the preferred option for a growing number of patients.

By Post-Transplant Care Insights

Why did the Immunosuppressive Therapy Segment Dominate the Market in 2025?

The immunosuppressive therapy segment is dominant in the heart transplant market in 2025. Immunosuppressants lower the chances that the body will reject the transplanted organ. Immunosuppression aims to prevent or manage cardiac allograft rejection while reducing drug toxicities, as well as the major sequelae of immunosuppression, such as infection and malignancy. Immunosuppressive regimens consist of a mixture of many agents used concurrently, and the regimen design incorporates several general principles.

Cardiac Rehabilitation

Whereas the cardiac rehabilitation segment is the fastest-growing in the market, as CR has been shown to enhance different important patient results, including exercise capacity, control of cardiovascular challenging factors, and quality of life. This integrates exercise and education to support improving health and recovery after a heart transplant. CR helps enhance the function of the heart, growing peak oxygen uptake (peak) and encouraging cardiac reinnervation.

Regional Insights

How did North America dominate the Market in 2025?

In 2025, North America dominated the heart transplant market, as this region's adoption of three-dimensional (3D) bioprinting technology for tissue engineering has shown increasing advantages in generating micro-scale cardiac tissues. The presence of major companies that adopt advanced technology like HeartFlow leads the market in renovating cardiovascular care. It is successful digital health care organizations in the world that drive the growth of the market.

U.S. Market Trends

In the U.S., nearly 6.7 million Americans live with heart failure, with a per-person lifetime occurrence estimated at 24%. With a projected 1 in 5 Americans 40 years and older expected to experience heart failure and 1 in 5 U.S. citizens expected to be 65 years or older by 2050, which growing demand for heart transplant solutions. The U.S. leads in advancing and adopting advanced technologies such as Mechanical Circulatory Support (MCS), total artificial hearts, and ventricular assist devices (VADs), which drives the growth of the market.

Asia Pacific: Increasing Healthcare Capabilities

Asia Pacific is expected to see rapid growth in the heart transplant market, driven by improving healthcare abilities and increasing patient pool in evolving nations, and a growing geriatric population are in the significant factors attributed to the Asia Pacific. The number of older persons is growing rapidly, contributing to increasing incidences of cancer and chronic diseases. Unhealthy dietary patterns, high blood pressure, and air pollution are prevalent IHD challenging factors in the Asia-Pacific region, which drives the growth of the market.

India Market Trends

India’s cardiac transplantation programme is the number one programme in the Asia Pacific, with an average heart transplantation rate of 0.2 per million population. Among both men and women in India, heart diseases range from 1.3 to 4.6 million, with a yearly incidence of 491,600 to 1.8 million according to the Associated Chambers of Commerce and Industry of India (ASSOCHAM). Heart Transplantation in India emphasizes prolonging life with advanced quality for these patients with complex heart failure.

Value Chain Analysis

R&D:

• Major research and development (R&D) in heart transplantation occurs in organ preservation and transportation technologies, mechanical circulatory support (MCS) devices, immunosuppression and rejection monitoring, genetic engineering and xenotransplantation, clinical trials, and patient results research.
• Key Players: TransMedics, Inc. and Abbott Laboratories

Manufacturing Processes:

• Major manufacturing processes involve organ preservation, mechanical circulatory support devices, bioartificial organ engineering, and ablation of consumables.
• Key Players: Medtronic plc and Paragonix Technologies, Inc.

Patient Services:

• Patient services in a heart transplant program are comprehensive, covering the entire journey from initial evaluation to long-term post-operative care.
• Key Players: Novartis AG and Astellas Pharma Inc.

Latest Updates of Key Players in the Heart Transplant Market

SWOT Analysis

Strengths

• Heart transplantation significantly improves the quality of life by lessening symptoms such as fatigue, shortness of breath, and chest pain, which are often associated with heart failure.
• Developments in healthcare technology and immunosuppressive therapies improved the success rates of heart transplants, creating them a viable option for major patients.

Weaknesses

• The receiver's immune system may recognize the novel heart as a foreign object and attempt to attack it.
• To prevent rejection, patients must take significant immunosuppressant medications for the rest of their lives.

Opportunities

• Novel technologies such as thoracoabdominal normothermic regional perfusion (NRP), which enables organs to continue to be perfused inside the donor at normal body temperatures, supports expand the time an organ can be used for a transplant.
• Recent developments in artificial hearts, mechanical circulatory support tools, and xenotransplantation have tackled both technological and ethical complexities, offering novel services for managing complex heart failure.

Threat

• Lifelong medications need to prevent rejection, weaken the immune system, creating patients susceptible to serious infections, cancer, and kidney damage.

Recent Developments in the Heart Transplant Market

• In February 2026, TransMedics Group, Inc., a healthcare technology organization that is renovating organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced that the U.S. Food and Drug Administration (FDA) had granted approval of its Investigational Device Exemption (IDE) for the Next-Generation OCS ENHANCE Heart trial.
• In January 2026, Apollo Hospitals, Chennai, continues to set national benchmarks in the treatment of advanced heart and lung disease, driven by one of India’s most comprehensive heart, lung, and ECMO-supported transplant programs. The transplant team, with significant national and international experience, has performed 600+ heart and lung transplants and managed over 2,000 transplant patients.

Segments Covered in the Report

By Age Group

• Pediatric
• Adult
• Geriatrics

By Type of Donor

• Deceased Donor
• Living Donor

By Surgical Technique

• Orthotopic Transplantation
• Heterotopic Transplantation
• Minimally Invasive Surgery

By Region

• North America
  • U.S.
  • Canada 
  • Mexico 
  • Rest of North America
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Europe 
  • Western Europe 
    • Germany 
    • Italy
    • France
    • Netherlands
    • Spain
    • Portugal 
    • Belgium
    • Ireland
    • UK 
    • Iceland 
    • Switzerland
    • Poland
    • Rest of Western Europe
  • Eastern Europe 
    • Austria
    • Russia & Belarus 
    • Türkiye
    • Albania 
    • Rest of Eastern Europe 
• Asia Pacific
  • China 
  • Taiwan
  • India 
  • Japan 
  • Australia and New Zealand
  • ASEAN Countries (Singapore, Malaysia)
  • South Korea 
  • Rest of APAC 
• MEA 
  • GCC Countries
    • Saudi Arabia 
    • United Arab Emirates (UAE)
    • Qatar 
    • Kuwait 
    • Oman 
    • Bahrain 
  • South Africa
  • Egypt 
  • Rest of MEA